Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Invested Capital: 2020-2025

Historic Invested Capital for GeneDx Holdings (WGS) over the last 5 years, with Sep 2025 value amounting to $347.1 million.

  • GeneDx Holdings' Invested Capital rose 33.22% to $347.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $347.1 million, marking a year-over-year increase of 33.22%. This contributed to the annual value of $251.0 million for FY2024, which is 7.14% up from last year.
  • As of Q3 2025, GeneDx Holdings' Invested Capital stood at $347.1 million, which was up 4.46% from $332.3 million recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' Invested Capital registered a high of $648.3 million during Q2 2022, and its lowest value of -$565.2 million during Q2 2021.
  • Moreover, its 3-year median value for Invested Capital was $263.5 million (2024), whereas its average is $286.3 million.
  • Its Invested Capital has fluctuated over the past 5 years, first soared by 7,940.41% in 2021, then crashed by 54.48% in 2023.
  • Over the past 5 years, GeneDx Holdings' Invested Capital (Quarterly) stood at $399.1 million in 2021, then tumbled by 34.85% to $260.0 million in 2022, then fell by 9.88% to $234.3 million in 2023, then rose by 7.14% to $251.0 million in 2024, then spiked by 33.22% to $347.1 million in 2025.
  • Its last three reported values are $347.1 million in Q3 2025, $332.3 million for Q2 2025, and $312.9 million during Q1 2025.